BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs

Reuters
Yesterday
BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs

Feb 11 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:

  • MADRIGAL EXPANDS ITS MASH PIPELINE WITH EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR SIX PRECLINICAL SIRNA PROGRAMS

  • MADRIGAL PHARMACEUTICALS INC - ANNOUNCES EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SUZHOU RIBO

  • MADRIGAL PHARMACEUTICALS INC - RIBO TO RECEIVE $60 MILLION UPFRONT, POTENTIAL $4.4 BILLION IN PAYMENTS

Source text: ID:nGNX44BPrz

Further company coverage: MDGL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10